Published in Cancer Weekly, September 12th, 2000
"HAART has significantly reduced the KS incidence among HIV infected patients," reported E. Vaccher and colleagues from the Italian Cooperative Group on AIDS and Tumors (GICAT). "To evaluated the anti-KS activity of HAART in patients with NYU stage I-III and slowly progressive disease, we performed a Phase II multicentric study."
Vaccher et al. presented data from their study at the 36th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana. The title of their presentation was "Highly active...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.